PL410218A1 - Sposób wytwarzania stabilnej liofilizowanej kompozycji obejmującej monomeryczne koniugaty pochodna kalicheamycyny/przeciwciało anty-CD22, kompozycja otrzymana tym sposobem oraz jej zastosowanie - Google Patents

Sposób wytwarzania stabilnej liofilizowanej kompozycji obejmującej monomeryczne koniugaty pochodna kalicheamycyny/przeciwciało anty-CD22, kompozycja otrzymana tym sposobem oraz jej zastosowanie

Info

Publication number
PL410218A1
PL410218A1 PL410218A PL41021803A PL410218A1 PL 410218 A1 PL410218 A1 PL 410218A1 PL 410218 A PL410218 A PL 410218A PL 41021803 A PL41021803 A PL 41021803A PL 410218 A1 PL410218 A1 PL 410218A1
Authority
PL
Poland
Prior art keywords
applications
stable lyophilized
antibody anti
producing stable
containing monomeric
Prior art date
Application number
PL410218A
Other languages
English (en)
Other versions
PL224001B1 (pl
Inventor
Arthur Kunz
Justin Keith Moran
Joseph Thomas Rubino
Neera Jain
Eugene Joseph Vidunas
John Mclean Simpson
Paul David Robbins
Nishith Merchant
John Francis Dijoseph
Mark Edward Ruppen
Nitin Krishnaji Damle
Andrew George Popplewell
Original Assignee
Wyeth Holdings Corporation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=29401497&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PL410218(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Wyeth Holdings Corporation filed Critical Wyeth Holdings Corporation
Publication of PL410218A1 publication Critical patent/PL410218A1/pl
Publication of PL224001B1 publication Critical patent/PL224001B1/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/17—Amides, e.g. hydroxamic acids having the group >N—C(O)—N< or >N—C(S)—N<, e.g. urea, thiourea, carmustine
    • A61K31/175—Amides, e.g. hydroxamic acids having the group >N—C(O)—N< or >N—C(S)—N<, e.g. urea, thiourea, carmustine having the group, >N—C(O)—N=N— or, e.g. carbonohydrazides, carbazones, semicarbazides, semicarbazones; Thioanalogues thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6807—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug or compound being a sugar, nucleoside, nucleotide, nucleic acid, e.g. RNA antisense
    • A61K47/6809—Antibiotics, e.g. antitumor antibiotics anthracyclins, adriamycin, doxorubicin or daunomycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/54—F(ab')2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Zoology (AREA)
  • Cell Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Oncology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Hematology (AREA)
  • Plant Pathology (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Mycology (AREA)
  • Toxicology (AREA)

Abstract

Wynalazek dotyczy sposobu wytwarzania stabilnej liofilizowanej kompozycji obejmującej monomeryczne koniugaty pochodna kalicheamycyny/przeciwciało anty-CD22, kompozycji otrzymanej tym sposobem oraz jej zastosowania do wytwarzania leku do leczenia zaburzenia proliferacyjnego.
PL410218A 2002-05-02 2003-05-02 Sposób wytwarzania stabilnej liofilizowanej kompozycji obejmującej monomeryczne koniugaty pochodna kalicheamycyny/przeciwciało anty-CD22, kompozycja otrzymana tym sposobem oraz jej zastosowanie PL224001B1 (pl)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US37744002P 2002-05-02 2002-05-02

Publications (2)

Publication Number Publication Date
PL410218A1 true PL410218A1 (pl) 2015-03-30
PL224001B1 PL224001B1 (pl) 2016-11-30

Family

ID=29401497

Family Applications (5)

Application Number Title Priority Date Filing Date
PL413302A PL228741B1 (pl) 2002-05-02 2003-05-02 Koniugaty pochodna kalicheamycyny/przeciwciało przeciwko CD22 oraz ich zastosowanie
PL410218A PL224001B1 (pl) 2002-05-02 2003-05-02 Sposób wytwarzania stabilnej liofilizowanej kompozycji obejmującej monomeryczne koniugaty pochodna kalicheamycyny/przeciwciało anty-CD22, kompozycja otrzymana tym sposobem oraz jej zastosowanie
PL374523A PL222725B1 (pl) 2002-05-02 2003-05-02 Sposób wytwarzania kompozycji i kompozycja zawierająca monomeryczne koniugaty pochodna kalicheamycyny/przeciwciało anty-CD22 o zmniejszonej zawartości frakcji niskoskoniugowanej
PL410219A PL224150B1 (pl) 2002-05-02 2003-05-02 Kompozycja zawierająca koniugat leku obejmujący pochodne kalicheamycyny i przeciwciało, oraz kompozycja farmaceutyczna ją zawierająca
PL411824A PL224844B1 (pl) 2002-05-02 2003-05-02 Zastosowanie kompozycji zawierającej monomeryczne koniugaty pochodna kalicheamycyny/przeciwciało anty-CD22

Family Applications Before (1)

Application Number Title Priority Date Filing Date
PL413302A PL228741B1 (pl) 2002-05-02 2003-05-02 Koniugaty pochodna kalicheamycyny/przeciwciało przeciwko CD22 oraz ich zastosowanie

Family Applications After (3)

Application Number Title Priority Date Filing Date
PL374523A PL222725B1 (pl) 2002-05-02 2003-05-02 Sposób wytwarzania kompozycji i kompozycja zawierająca monomeryczne koniugaty pochodna kalicheamycyny/przeciwciało anty-CD22 o zmniejszonej zawartości frakcji niskoskoniugowanej
PL410219A PL224150B1 (pl) 2002-05-02 2003-05-02 Kompozycja zawierająca koniugat leku obejmujący pochodne kalicheamycyny i przeciwciało, oraz kompozycja farmaceutyczna ją zawierająca
PL411824A PL224844B1 (pl) 2002-05-02 2003-05-02 Zastosowanie kompozycji zawierającej monomeryczne koniugaty pochodna kalicheamycyny/przeciwciało anty-CD22

Country Status (33)

Country Link
US (6) US8153768B2 (pl)
EP (3) EP2371392B1 (pl)
JP (5) JP5153057B2 (pl)
KR (2) KR101125524B1 (pl)
CN (1) CN100482277C (pl)
AU (2) AU2003231293A1 (pl)
BE (1) BE2017C049I2 (pl)
BR (3) BR122019027966B8 (pl)
CA (2) CA2483552A1 (pl)
CR (3) CR7557A (pl)
CY (4) CY1116634T1 (pl)
DK (3) DK3127553T3 (pl)
EC (1) ECSP045445A (pl)
ES (3) ES2545745T3 (pl)
FR (1) FR17C1054I2 (pl)
HU (4) HUE027590T2 (pl)
IL (2) IL164946A (pl)
LT (3) LT3127553T (pl)
LU (1) LUC00044I2 (pl)
MX (1) MXPA04010792A (pl)
NL (1) NL300903I2 (pl)
NO (3) NO339730B1 (pl)
NZ (2) NZ573563A (pl)
PH (2) PH12013501159A1 (pl)
PL (5) PL228741B1 (pl)
PT (3) PT2371392E (pl)
RU (3) RU2422157C3 (pl)
SG (3) SG10201700289RA (pl)
SI (3) SI1507556T1 (pl)
TW (2) TWI379693B (pl)
UA (1) UA88599C2 (pl)
WO (1) WO2003092623A2 (pl)
ZA (2) ZA200409752B (pl)

Families Citing this family (154)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6905669B2 (en) 2001-04-24 2005-06-14 Supergen, Inc. Compositions and methods for reestablishing gene transcription through inhibition of DNA methylation and histone deacetylase
US20110045005A1 (en) * 2001-10-19 2011-02-24 Craig Crowley Compositions and methods for the treatment of tumor of hematopoietic origin
PT2371392E (pt) * 2002-05-02 2015-10-07 Wyeth Holdings Llc Conjugados de derivado da caliqueamicina - transportador
GB0210121D0 (en) 2002-05-02 2002-06-12 Celltech R&D Ltd Biological products
AR048098A1 (es) * 2004-03-15 2006-03-29 Wyeth Corp Conjugados de caliqueamicina
WO2005115141A1 (ja) * 2004-05-26 2005-12-08 National University Corporation Kagawa University 希少糖を利用した細胞・組織・臓器保存液及び該液を用いる保存方法
TW200621282A (en) * 2004-08-13 2006-07-01 Wyeth Corp Stabilizing formulations
TWI384069B (zh) 2004-08-27 2013-02-01 Pfizer Ireland Pharmaceuticals 多胜肽之製法
US7335491B2 (en) 2004-08-27 2008-02-26 Wyeth Research Ireland Limited Production of anti-abeta
US7300773B2 (en) 2004-08-27 2007-11-27 Wyeth Research Ireland Limited Production of TNFR-Ig
US20060045877A1 (en) * 2004-08-30 2006-03-02 Goldmakher Viktor S Immunoconjugates targeting syndecan-1 expressing cells and use thereof
EP1786469A2 (en) * 2004-09-10 2007-05-23 Wyeth a Corporation of the State of Delaware Humanized anti-5t4 antibodies and anti-5t4 antibody / calicheamicin conjugates
EP1661584A1 (en) * 2004-11-26 2006-05-31 Heinz Dr. Faulstich Use of conjugates of amatoxins and phallotoxins with macromolecules for cancer and inflammation therapy
US20110166319A1 (en) * 2005-02-11 2011-07-07 Immunogen, Inc. Process for preparing purified drug conjugates
US7250416B2 (en) 2005-03-11 2007-07-31 Supergen, Inc. Azacytosine analogs and derivatives
US20070003559A1 (en) * 2005-07-01 2007-01-04 Wyeth Methods of determining pharmacokinetics of targeted therapies
US7678832B2 (en) 2005-08-16 2010-03-16 Synta Pharmaceuticals Corp. Bis(thio-hydrazide amide) formulation
CA2620343C (en) 2005-08-24 2013-01-08 Immunogen, Inc. Process for preparing antibody maytansinoid conjugates
US7700567B2 (en) 2005-09-29 2010-04-20 Supergen, Inc. Oligonucleotide analogues incorporating 5-aza-cytosine therein
CA2631714C (en) 2005-12-02 2014-09-16 Novartis Ag Nanoparticles for use in immunogenic compositions
BRPI0619476A2 (pt) * 2005-12-05 2011-10-04 Wyeth Corp composições de interleucina-11 e métodos de uso
PT1994055E (pt) 2006-03-10 2014-09-15 Wyeth Llc Anticorpos anti-5t4 e utilizações dos mesmos
ES2371085T3 (es) * 2006-05-27 2011-12-27 Faulstich, Heinz, Dr. Utilización de conjugados de amatoxinas o falotoxinas con macromoléculas para la terapia tumoral y de la inflamación.
US8129145B2 (en) 2006-07-13 2012-03-06 Wyeth Llc Production of glycoproteins
EP2057117A2 (en) 2006-08-21 2009-05-13 Synta Pharmaceuticals Corporation Compounds for treating proliferative disorders
MX2009003542A (es) * 2006-10-12 2009-04-15 Wyeth Corp Metodos y composiciones con opalescencia reducida.
CA2666317C (en) * 2006-11-03 2013-08-06 Wyeth Glycolysis-inhibiting substances in cell culture
WO2008070569A2 (en) * 2006-12-01 2008-06-12 Medarex, Inc. Human antibodies that bind cd22 and uses thereof
CA2671900A1 (en) * 2006-12-22 2008-07-03 The Regents Of The University Of California Macromolecular conjugates of cystic fibrosis transmembrane conductance regulator protein inhibitors and uses thereof
BRPI0806680A2 (pt) * 2007-01-16 2015-06-16 Wyeth Corp Tratamento, detecção e monitoramento de inflamação via trem-1
EP2924113B1 (en) * 2007-03-02 2019-04-10 Wyeth LLC Use of copper and glutamate in cell culture for production of polypeptides
EP2155258B1 (en) 2007-05-22 2017-08-16 Wyeth LLC Improved processes for making hydrazides
PE20090309A1 (es) * 2007-06-04 2009-04-18 Wyeth Corp Conjugado portador-caliqueamicina y un metodo de deteccion de caliqueamicina
EP2211904B1 (en) * 2007-10-19 2016-08-17 Seattle Genetics, Inc. Cd19 binding agents and uses thereof
BRPI0819593A2 (pt) * 2007-12-21 2015-05-05 Genentech Inc "método para tratamento de um paciente com artrite reumatóide (ra)"
JP5990365B2 (ja) * 2007-12-26 2016-09-14 バイオテスト・アクチエンゲゼルシヤフト Ｃｄ１３８を標的とする剤及びその使用
RU2547939C2 (ru) * 2007-12-26 2015-04-10 Биотест Аг Иммуноконъюгаты, направленные на cd138, и их применение
EP2238169A1 (en) * 2007-12-26 2010-10-13 Biotest AG Method of decreasing cytotoxic side-effects and improving efficacy of immunoconjugates
US9446146B2 (en) * 2007-12-26 2016-09-20 Biotest Ag Methods and agents for improving targeting of CD138 expressing tumor cells
US20090186026A1 (en) * 2008-01-18 2009-07-23 Wyeth Ephrin and eph receptor agonists for modulation of bone formation and resorption
WO2009124109A1 (en) 2008-04-04 2009-10-08 The Government Of The U.S. A. As Represented By The Secretary Of The Dept. Of Health &Human Services Human monoclonal antibodies specific for cd22
FR2930443B1 (fr) * 2008-04-29 2010-06-25 Oreal Produit extemporane de soin a base d'un lyophilisat de microorganisme et de tensioactif(s) de hlb superieur ou egal a 12
KR101892411B1 (ko) 2008-04-30 2018-08-27 이뮤노젠 아이엔씨 가교제 및 그 용도
CA2761959C (en) * 2009-06-03 2018-09-11 Immunogen, Inc. Conjugation methods
WO2011098518A2 (en) * 2010-02-11 2011-08-18 Ablynx Nv Delivery of immunoglobulin variable domains and constructs thereof
CA2807552A1 (en) 2010-08-06 2012-02-09 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
JP2013535981A (ja) 2010-08-20 2013-09-19 ワイス・エルエルシー 成長因子不含適合細胞の細胞培養
SMT202200321T1 (it) 2010-10-01 2022-09-14 Modernatx Inc Acidi ribonucleici contenenti n1-metil-pseudouracili e loro usi
WO2012065161A2 (en) 2010-11-12 2012-05-18 Scott & White Healthcare Antibodies to tumor endothelial marker 8
US8512679B2 (en) * 2011-03-04 2013-08-20 Elwha Llc Glassy compositions
DK2691155T3 (en) 2011-03-29 2019-03-04 Immunogen Inc PREPARATION OF MAYTANSINOID ANTIBODY CONJUGATES BY A STEP PROCEDURE
DE12722942T1 (de) 2011-03-31 2021-09-30 Modernatx, Inc. Freisetzung und formulierung von manipulierten nukleinsäuren
CA2845585C (en) 2011-08-30 2020-02-18 Astex Pharmaceuticals, Inc. Decitabine derivative formulations
US9464124B2 (en) 2011-09-12 2016-10-11 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
JP6113737B2 (ja) 2011-10-03 2017-04-12 モデルナティエックス インコーポレイテッドＭｏｄｅｒｎａＴＸ，Ｉｎｃ． 修飾型のヌクレオシド、ヌクレオチドおよび核酸、ならびにそれらの使用方法
EP2768944B2 (en) 2011-10-21 2023-11-22 Pfizer Inc. Addition of iron to improve cell culture
CN104302324A (zh) 2011-12-08 2015-01-21 生物测试股份公司 靶向cd138的免疫偶联物的用途
CA3018046A1 (en) 2011-12-16 2013-06-20 Moderna Therapeutics, Inc. Modified nucleoside, nucleotide, and nucleic acid compositions
US10501512B2 (en) 2012-04-02 2019-12-10 Modernatx, Inc. Modified polynucleotides
JP2015513913A (ja) 2012-04-02 2015-05-18 モデルナ セラピューティクス インコーポレイテッドＭｏｄｅｒｎａ Ｔｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ． 修飾ポリヌクレオチド
US9283287B2 (en) 2012-04-02 2016-03-15 Moderna Therapeutics, Inc. Modified polynucleotides for the production of nuclear proteins
US9572897B2 (en) 2012-04-02 2017-02-21 Modernatx, Inc. Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins
AU2013286680B2 (en) 2012-07-03 2018-07-05 Washington University Antibodies to tau
US8883979B2 (en) 2012-08-31 2014-11-11 Bayer Healthcare Llc Anti-prolactin receptor antibody formulations
RU2018122734A (ru) 2012-10-04 2018-07-24 Иммуноджен, Инк. Использование пвдф-мембраны для очистки конъюгатов клеточно-связывающий агент-цитотоксический агент
ES2701076T3 (es) 2012-11-24 2019-02-20 Hangzhou Dac Biotech Co Ltd Enlazadores hidrofílicos y sus usos para la conjugación de fármacos a las moléculas que se unen a las células
ES2921623T3 (es) 2012-11-26 2022-08-30 Modernatx Inc ARN modificado terminalmente
ES2714951T3 (es) 2012-12-21 2019-05-30 Bioalliance Cv Enlazadores autoinmoladores hidrófilos y conjugados de los mismos
WO2014113203A1 (en) 2013-01-17 2014-07-24 Case Western Reserve University Viral nanoparticle multimers
US8980864B2 (en) 2013-03-15 2015-03-17 Moderna Therapeutics, Inc. Compositions and methods of altering cholesterol levels
JP6207721B2 (ja) * 2013-05-02 2017-10-04 エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト アフコシル化ｃｄ２０抗体のｃｄ２２抗体−薬物コンジュゲートとの併用療法
US10023626B2 (en) 2013-09-30 2018-07-17 Modernatx, Inc. Polynucleotides encoding immune modulating polypeptides
MX2016004249A (es) 2013-10-03 2016-11-08 Moderna Therapeutics Inc Polinulcleotidos que codifican el receptor de lipoproteina de baja densidad.
CA2929283C (en) * 2013-11-04 2022-07-19 Pfizer Inc. Intermediates and methods for synthesizing calicheamicin derivatives
RU2016119491A (ru) 2013-11-04 2017-12-11 Пфайзер Инк. Конъюгаты антитела к efna4 с лекарственным средством
CN114262344A (zh) 2014-02-28 2022-04-01 杭州多禧生物科技有限公司 带电荷链接体及其在共轭反应上的应用
EP3119876B1 (en) 2014-03-19 2024-12-18 Pfizer Inc. Method of cell culture
US11998594B2 (en) 2014-04-02 2024-06-04 Case Western Reserve University Anti-cancer plant virus particles linked to HER2 antigens
US9950077B2 (en) 2014-06-20 2018-04-24 Bioalliance C.V. Anti-folate receptor alpha (FRA) antibody-drug conjugates and methods of using thereof
TW202136296A (zh) 2014-06-27 2021-10-01 美商Ｃ２Ｎ醫療診斷有限責任公司 人類化抗-tau抗體
GB201412658D0 (en) 2014-07-16 2014-08-27 Ucb Biopharma Sprl Molecules
US9925281B2 (en) 2014-08-05 2018-03-27 Case Western Reserve University Coated plant virus imaging agents
JP6731405B2 (ja) 2014-11-07 2020-07-29 ケース ウエスタン リザーブ ユニバーシティ ウイルス粒子を用いた癌免疫療法
US12465624B2 (en) 2018-05-08 2025-11-11 Case Western Reserve University Cancer immunotherapy using virus particles and immune checkpoint therapy
EP3280454A1 (en) 2015-04-07 2018-02-14 Memorial Sloan Kettering Cancer Center Nanoparticle immunoconjugates
MA41959A (fr) * 2015-04-21 2018-02-28 Abbvie Stemcentrx Llc Constructions de calichéamicine d'acide nucléique et leurs procédés d'utilisation
GB201506870D0 (en) 2015-04-22 2015-06-03 Ucb Biopharma Sprl Method
US9708412B2 (en) 2015-05-21 2017-07-18 Harpoon Therapeutics, Inc. Trispecific binding proteins and methods of use
EP3313527B1 (en) 2015-06-29 2021-02-24 Case Western Reserve University Anticancer drug-containing plant virus particles
CA2991167A1 (en) 2015-07-02 2017-01-05 Otsuka Pharmaceutical Co., Ltd. Lyophilized pharmaceutical compositions
EP3319936B1 (en) 2015-07-12 2025-12-17 Hangzhou Dac Biotech Co., Ltd. Bridge linkers for conjugation of cell-binding molecules
US9839687B2 (en) 2015-07-15 2017-12-12 Suzhou M-Conj Biotech Co., Ltd. Acetylenedicarboxyl linkers and their uses in specific conjugation of a cell-binding molecule
EP3725332B1 (en) 2015-07-16 2023-10-04 Case Western Reserve University Plant virus particles for delivery of antimitotic agents
GB201601077D0 (en) 2016-01-20 2016-03-02 Ucb Biopharma Sprl Antibody molecule
GB201601073D0 (en) 2016-01-20 2016-03-02 Ucb Biopharma Sprl Antibodies
GB201601075D0 (en) 2016-01-20 2016-03-02 Ucb Biopharma Sprl Antibodies molecules
EP4446338A3 (en) 2015-09-23 2025-05-07 Pfizer Inc. Cells and method of cell culture
EP3374493A1 (en) 2015-11-09 2018-09-19 Bristol-Myers Squibb Company Methods to manipulate quality attributes of polypeptides produced in cho cells
JP7078536B2 (ja) 2016-01-08 2022-05-31 アルトゥルバイオ， インコーポレイテッド 四価抗ｐｓｇｌ－１抗体とその使用
US20170281758A1 (en) * 2016-03-29 2017-10-05 Sorrento Therapeutics, Inc. Calicheamicin antibody drug conjugates linking an amidoacetyl group to a sugar moiety on calicheamicin
IL261999B2 (en) 2016-04-05 2023-04-01 Pfizer Cell culture process
US11623958B2 (en) 2016-05-20 2023-04-11 Harpoon Therapeutics, Inc. Single chain variable fragment CD3 binding proteins
WO2017201488A1 (en) 2016-05-20 2017-11-23 Harpoon Therapeutics, Inc. Single domain serum albumin binding protein
GB201610512D0 (en) 2016-06-16 2016-08-03 Autolus Ltd Chimeric antigen receptor
EP3487527A4 (en) 2016-07-21 2020-03-11 Case Western Reserve University Plant virus or virus-like particle constructs
US12433840B2 (en) 2016-11-03 2025-10-07 Case Western Reserve University Melt processed viral nanoparticle constructs
AU2017354004C1 (en) 2016-11-03 2023-08-31 Case Western Reserve University Melt processed viral nanoparticle constructs
KR20220147719A (ko) 2016-11-14 2022-11-03 항저우 디에이씨 바이오테크 씨오, 엘티디 결합 링커, 그러한 결합 링커를 함유하는 세포 결합 분자-약물 결합체, 링커를 갖는 그러한 결합체의 제조 및 사용
US11590183B2 (en) 2017-03-10 2023-02-28 Case Western Reserve University Cancer immunotherapy using virus particles
JP7177076B2 (ja) 2017-03-16 2022-11-22 ファイザー・インク チロシン原栄養性
CN113896792B (zh) 2017-05-12 2025-08-22 哈普恩治疗公司 间皮素结合蛋白质
US11672840B2 (en) 2017-05-17 2023-06-13 Case Western Reserve University Anticancer trail-targeted plant virus particles
EP3661522A2 (en) 2017-08-03 2020-06-10 Otsuka Pharmaceutical Co., Ltd. Drug compound and purification methods thereof
JP2020533983A (ja) 2017-09-15 2020-11-26 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ 目的のポリペプチドのラージスケールの製造間のオンラインバイオマス静電容量モニタリング
IL315737A (en) 2017-10-13 2024-11-01 Harpoon Therapeutics Inc B-cell maturation antigen-binding proteins
BR112020007196A2 (pt) 2017-10-13 2020-12-01 Harpoon Therapeutics, Inc. proteínas triespecíficas e métodos de uso
WO2019084555A1 (en) 2017-10-27 2019-05-02 Case Western Reserve University TYMOVIRUS VIRUSES AND VIRAL TYPE PARTICLES USEFUL AS NANOVECTORS FOR IMAGING AND THERAPEUTIC AGENTS
JP7462566B2 (ja) 2018-03-16 2024-04-05 ブリストル－マイヤーズ スクイブ カンパニー タンパク質生産の間の代謝酵素活性およびジスルフィド結合還元
CN110507824A (zh) * 2018-05-21 2019-11-29 荣昌生物制药（烟台）有限公司 一种抗间皮素抗体及其抗体药物缀合物
CN112135843A (zh) 2018-05-30 2020-12-25 艾伯维施特姆森特克斯有限责任公司 抗sez6抗体药物缀合物和使用方法
WO2020061482A1 (en) 2018-09-21 2020-03-26 Harpoon Therapeutics, Inc. Egfr binding proteins and methods of use
IL281683B2 (en) 2018-09-25 2023-04-01 Harpoon Therapeutics Inc dll3 binding proteins and methods of use
EP3883610A4 (en) 2018-11-20 2022-11-02 Cornell University MACROCYCLIC COMPLEXES OF RADIONUCLIDES AND THEIR USE IN CANCER RADIATION THERAPY
WO2020115655A1 (en) 2018-12-06 2020-06-11 Pfizer Inc. Cells with reduced inhibitor production and methods of use thereof
JP2022523763A (ja) * 2019-02-13 2022-04-26 コイミューン インコーポレイテッド キメラ抗原受容体を発現する細胞とモノクローナル抗体との組み合わせを用いたがん免疫療法
US20220152179A1 (en) 2019-03-19 2022-05-19 Fundació Privada Institut D'investigació Oncològica De Vall Hebron Combination therapy with omomyc and an antibody binding pd-1 or ctla-4 for the treatment of cancer
US11390853B2 (en) 2019-04-26 2022-07-19 Case Western Reserve University Freeze dried viral nanoparticle constructs
WO2021007361A1 (en) * 2019-07-08 2021-01-14 Mythic Therapeutics, Inc. Antigen-binding protein constructs and uses thereof
WO2021024020A1 (en) 2019-08-06 2021-02-11 Astellas Pharma Inc. Combination therapy involving antibodies against claudin 18.2 and immune checkpoint inhibitors for treatment of cancer
US11896676B2 (en) 2019-08-07 2024-02-13 Case Western Reserve University Targeting cancer cells and tissue using filamentous plant virus particles
EP4069312A4 (en) * 2019-12-04 2024-03-27 The Research Foundation for the State University of New York COMPOSITIONS AND METHODS FOR REDUCING OFF-TARGET TOXICITY OF ANTIBODY-DRUG CONJUGATES
US12203073B2 (en) 2019-12-20 2025-01-21 Case Western Reserve University Plant viral RNA delivery nanoparticles and uses thereof
US11529430B2 (en) 2019-12-20 2022-12-20 Case Western Reserve University Polydopamine decorated tobacco mosaic theranostic virus nanoparticles
CA3182579A1 (en) 2020-07-07 2022-01-13 Ugur Sahin Therapeutic rna for hpv-positive cancer
WO2022135666A1 (en) 2020-12-21 2022-06-30 BioNTech SE Treatment schedule for cytokine proteins
WO2022135667A1 (en) 2020-12-21 2022-06-30 BioNTech SE Therapeutic rna for treating cancer
TW202245808A (zh) 2020-12-21 2022-12-01 德商拜恩迪克公司 用於治療癌症之治療性ｒｎａ
CN112724263B (zh) * 2021-04-02 2021-08-03 上海偌妥生物科技有限公司 改造抗cd20单克隆抗体以提高其药物疗效的方法及其应用
AU2022312698A1 (en) 2021-07-13 2024-01-25 BioNTech SE Multispecific binding agents against cd40 and cd137 in combination therapy for cancer
TW202333802A (zh) 2021-10-11 2023-09-01 德商拜恩迪克公司 用於肺癌之治療性rna(二)
EP4426727A2 (en) 2021-11-03 2024-09-11 Hangzhou Dac Biotech Co., Ltd. Specific conjugation of an antibody
WO2023148598A1 (en) 2022-02-02 2023-08-10 Pfizer Inc. Cysteine prototrophy
JPWO2024058201A1 (pl) * 2022-09-16 2024-03-21
EP4608429A1 (en) 2022-10-25 2025-09-03 Peptomyc, S.L. Combination therapy for the treatment of cancer
CN120418289A (zh) 2022-12-14 2025-08-01 安斯泰来制药欧洲有限公司 结合cldn18.2和cd3的双特异性结合剂与免疫检查点抑制剂的联合疗法
EP4698631A1 (en) 2023-04-21 2026-02-25 Pfizer Inc. Improved cells and cell cultures
CN121335714A (zh) 2023-06-07 2026-01-13 瓦尔希伯伦私人肿瘤研究基金会 用于治疗癌症的与mek抑制剂的组合疗法
TW202502371A (zh) 2023-06-07 2025-01-16 瓦爾希伯倫私人腫瘤研究基金會 用於治療癌症的與ｂｒａｆ抑制劑的組合療法
EP4473974A1 (en) 2023-06-07 2024-12-11 Peptomyc, S.L. Omomyc and kras inhibitors combination therapy for the treatment of cancer
KR20250043317A (ko) * 2023-09-21 2025-03-28 주식회사 피노바이오 운반체-약물 접합체 및 dnmt-1 저해제의 병용 요법
WO2025120867A1 (en) 2023-12-08 2025-06-12 Astellas Pharma Inc. Combination therapy involving bispecific binding agents binding to cldn18.2 and cd3 and anti-vegfr2 antibodies
WO2025120866A1 (en) 2023-12-08 2025-06-12 Astellas Pharma Inc. Combination therapy involving bispecific binding agents binding to cldn18.2 and cd3 and agents stabilizing or increasing expression of cldn18.2
TW202541837A (zh) 2023-12-08 2025-11-01 日商安斯泰來製藥公司 含有結合至cldn18.2和cd3之雙特異性結合劑和穩定或增加cldn18.2表現之藥劑之組合療法
WO2026033885A1 (en) 2024-08-08 2026-02-12 Astellas Pharma Inc. Combination therapy involving bispecific binding agents binding to cldn18.2 and cd3 and agents stabilizing or increasing expression of cldn18.2

Family Cites Families (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4671958A (en) 1982-03-09 1987-06-09 Cytogen Corporation Antibody conjugates for the delivery of compounds to target sites
US4970198A (en) 1985-10-17 1990-11-13 American Cyanamid Company Antitumor antibiotics (LL-E33288 complex)
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US4771128A (en) * 1986-10-10 1988-09-13 Cetus Corporation Method of purifying toxin conjugates using hydrophobic interaction chromatography
US5037651A (en) 1987-01-30 1991-08-06 American Cyanamid Company Dihydro derivatives of LL-E33288 antibiotics
US5079233A (en) 1987-01-30 1992-01-07 American Cyanamid Company N-acyl derivatives of the LL-E33288 antitumor antibiotics, composition and methods for using the same
US5053394A (en) 1988-09-21 1991-10-01 American Cyanamid Company Targeted forms of methyltrithio antitumor agents
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5134075A (en) 1989-02-17 1992-07-28 Oncogen Limited Partnership Monoclonal antibody to novel antigen associated with human tumors
GB8928874D0 (en) 1989-12-21 1990-02-28 Celltech Ltd Humanised antibodies
AU8221191A (en) 1990-06-27 1992-01-23 Princeton University Probes for detecting mutant p53
CZ283717B6 (cs) 1991-03-06 1998-06-17 MERCK Patent Gesellschaft mit beschränkter Haftung Chimérická monoklonální protilátka, expresní vektory a farmaceutický prostředek
US5714350A (en) 1992-03-09 1998-02-03 Protein Design Labs, Inc. Increasing antibody affinity by altering glycosylation in the immunoglobulin variable region
US5686072A (en) 1992-06-17 1997-11-11 Board Of Regents, The University Of Texas Epitope-specific monoclonal antibodies and immunotoxins and uses thereof
US5484892A (en) * 1993-05-21 1996-01-16 Dana-Farber Cancer Institute, Inc. Monoclonal antibodies that block ligand binding to the CD22 receptor in mature B cells
US6180377B1 (en) 1993-06-16 2001-01-30 Celltech Therapeutics Limited Humanized antibodies
US5436265A (en) 1993-11-12 1995-07-25 Merck Frosst Canada, Inc. 1-aroyl-3-indolyl alkanoic acids and derivatives thereof useful as anti-inflammatory agents
US5712474A (en) * 1993-09-29 1998-01-27 Canon Kabushiki Kaisha Image processing apparatus for correcting blurring of an image photographed by a video camera
US6310185B1 (en) 1994-03-08 2001-10-30 Memorial Sloan Kettering Cancer Center Recombinant human anti-Lewis Y antibodies
US5773001A (en) 1994-06-03 1998-06-30 American Cyanamid Company Conjugates of methyltrithio antitumor agents and intermediates for their synthesis
IL114909A (en) 1994-08-12 1999-10-28 Immunomedics Inc Immunoconjugates and humanized antibodies specific for b-cell lymphoma and leukemia cells
ES2158048T5 (es) 1994-08-12 2009-11-04 The University Of Utah Research Foundation Mutaciones del gen ligado al cromosoma 17q, de susceptibilidad al cancer de mama y de ovario.
US5712374A (en) 1995-06-07 1998-01-27 American Cyanamid Company Method for the preparation of substantiallly monomeric calicheamicin derivative/carrier conjugates
US5714586A (en) 1995-06-07 1998-02-03 American Cyanamid Company Methods for the preparation of monomeric calicheamicin derivative/carrier conjugates
US6267958B1 (en) 1995-07-27 2001-07-31 Genentech, Inc. Protein formulation
US7147851B1 (en) 1996-08-15 2006-12-12 Millennium Pharmaceuticals, Inc. Humanized immunoglobulin reactive with α4β7 integrin
US20020141990A1 (en) 1996-11-01 2002-10-03 Smithkline Beecham Corporation Anti-RSV human monoclonal antibodies
US5980898A (en) 1996-11-14 1999-11-09 The United States Of America As Represented By The U.S. Army Medical Research & Material Command Adjuvant for transcutaneous immunization
CA2284665C (en) 1997-03-20 2010-08-17 David Fitzgerald Recombinant antibodies and immunoconjugates targeted to cd-22 bearing cells and tumors
US6183744B1 (en) 1997-03-24 2001-02-06 Immunomedics, Inc. Immunotherapy of B-cell malignancies using anti-CD22 antibodies
US6306393B1 (en) * 1997-03-24 2001-10-23 Immunomedics, Inc. Immunotherapy of B-cell malignancies using anti-CD22 antibodies
ATE230277T1 (de) 1997-06-13 2003-01-15 Genentech Inc Stabilisierte antikörperformulierung
AT408613B (de) 1998-06-17 2002-01-25 Immuno Ag Pharmazeutisches faktor vii-präparat
US6183477B1 (en) * 1998-09-04 2001-02-06 Smith & Nephew, Inc. Attachment tool for drill guide
KR100345463B1 (ko) 1998-11-19 2003-01-08 주)녹십자 B형간염바이러스의표면항원프리-s1에대한인간화항체및이의제조방법
JP2000226336A (ja) * 1998-11-30 2000-08-15 Sankyo Co Ltd 免疫グロブリン製剤
EP2154535A1 (en) 1998-12-10 2010-02-17 Bristol-Myers Squibb Company Protein scaffolds for antibody mimics and other binding proteins
ATE439860T1 (de) 1999-06-09 2009-09-15 Immunomedics Inc Immuntherapie von autoimmunerkrankungen durch die verwendung von b-zell spezifischen antikírpern
EP1210361B1 (en) * 1999-08-17 2004-04-14 Novo Nordisk Health Care AG Stabilisation of freeze-dried cake
TR200201006T2 (tr) 1999-10-12 2002-11-21 Connex Gesellschaft Zur Optimierung Von Forschung Und Dışkıda bulunan aside dirençli mikroorganizmaların tespitine ilişkin geliştirilmiş yöntem.
US20010046496A1 (en) 2000-04-14 2001-11-29 Brettman Lee R. Method of administering an antibody
GB0013810D0 (en) 2000-06-06 2000-07-26 Celltech Chiroscience Ltd Biological products
GB0210121D0 (en) * 2002-05-02 2002-06-12 Celltech R&D Ltd Biological products
PT2371392E (pt) 2002-05-02 2015-10-07 Wyeth Holdings Llc Conjugados de derivado da caliqueamicina - transportador

Also Published As

Publication number Publication date
TWI379693B (en) 2012-12-21
RU2602878C3 (ru) 2021-11-24
HUE027590T2 (hu) 2016-11-28
NO344509B1 (no) 2020-01-20
JP6872376B2 (ja) 2021-05-19
US20140235835A1 (en) 2014-08-21
DK1507556T3 (en) 2016-09-12
SG187991A1 (en) 2013-03-28
JP5756489B2 (ja) 2015-07-29
RU2004135101A (ru) 2005-06-27
US8835611B2 (en) 2014-09-16
HUS1700038I1 (hu) 2017-11-28
FR17C1054I2 (fr) 2019-01-11
RU2422157C3 (ru) 2021-04-23
EP2371392B1 (en) 2015-07-08
SI1507556T1 (sl) 2016-10-28
PL222725B1 (pl) 2016-08-31
US20160303252A1 (en) 2016-10-20
CR20130390A (es) 2013-11-08
PL224150B1 (pl) 2016-11-30
PT3127553T (pt) 2022-01-24
US8153768B2 (en) 2012-04-10
BRPI0309868B8 (pt) 2021-05-25
JP5441971B2 (ja) 2014-03-12
LT3127553T (lt) 2022-04-11
ZA200409752B (en) 2010-08-25
NO339730B1 (no) 2017-01-23
US20180339058A1 (en) 2018-11-29
CY1117973T1 (el) 2017-05-17
HUE030806T2 (hu) 2017-05-29
DK2371392T3 (en) 2015-08-31
HUE057124T2 (hu) 2022-04-28
CN100482277C (zh) 2009-04-29
IL230659A (en) 2016-02-29
ECSP045445A (es) 2005-01-28
SI3127553T1 (sl) 2022-02-28
CY1124900T1 (el) 2023-01-05
EP2371392A1 (en) 2011-10-05
LTC2371392I2 (lt) 2019-03-25
JP2005524700A (ja) 2005-08-18
SI2371392T1 (sl) 2015-10-30
LT1507556T (lt) 2016-10-10
CY1116634T1 (el) 2017-03-15
RU2422157C2 (ru) 2011-06-27
JP2015061875A (ja) 2015-04-02
CA2483552A1 (en) 2003-11-13
AU2009202609A1 (en) 2009-07-16
EP3127553B1 (en) 2021-12-01
NO20161431A1 (no) 2005-01-25
PL224844B1 (pl) 2017-02-28
JP2012051900A (ja) 2012-03-15
NZ573563A (en) 2010-10-29
PL410219A1 (pl) 2015-03-30
ZA201003874B (en) 2019-12-18
PL411824A1 (pl) 2015-08-17
BR0309868A (pt) 2005-10-18
RU2602878C2 (ru) 2016-11-20
NZ586071A (en) 2012-02-24
LTPA2017036I1 (lt) 2017-11-27
EP1507556A4 (en) 2009-01-07
JP2017105801A (ja) 2017-06-15
CY2017035I1 (el) 2018-04-04
SG165158A1 (en) 2010-10-28
CR20120364A (es) 2012-10-05
CR7557A (es) 2008-10-03
PL374523A1 (pl) 2005-10-31
IL164946A (en) 2015-06-30
ES2545745T3 (es) 2015-09-15
CY2017035I2 (el) 2018-04-04
PL413302A1 (pl) 2016-05-23
RU2016141576A (ru) 2018-05-03
BE2017C049I2 (pl) 2022-08-09
DK3127553T3 (da) 2022-01-31
NL300903I2 (nl) 2018-02-08
AU2003231293A1 (en) 2003-11-17
HK1070825A1 (en) 2005-06-30
CA2871117A1 (en) 2003-11-13
KR20050006220A (ko) 2005-01-15
US8747857B2 (en) 2014-06-10
AU2009202609B2 (en) 2012-07-26
PL224001B1 (pl) 2016-11-30
BR122019027966B8 (pt) 2021-07-27
HK1162926A1 (en) 2012-09-07
US20040192900A1 (en) 2004-09-30
CN1665532A (zh) 2005-09-07
WO2003092623A2 (en) 2003-11-13
PH12013501158A1 (en) 2015-11-09
FR17C1054I1 (pl) 2018-01-12
JP5153057B2 (ja) 2013-02-27
EP1507556A2 (en) 2005-02-23
ES2916174T3 (es) 2022-06-28
LUC00044I2 (pl) 2018-02-26
RU2016141576A3 (pl) 2018-05-03
RU2011108928A (ru) 2012-09-20
SG10201700289RA (en) 2017-02-27
BR122019027974B1 (pt) 2022-06-14
HUE057124T4 (hu) 2022-02-28
RU2678818C2 (ru) 2019-02-04
PH12013501158B1 (en) 2015-11-09
US9351986B2 (en) 2016-05-31
BRPI0309868B1 (pt) 2020-04-28
TWI438010B (zh) 2014-05-21
ES2593304T3 (es) 2016-12-07
PT1507556T (pt) 2016-09-28
BR122019027966B1 (pt) 2020-11-17
WO2003092623A3 (en) 2004-03-18
PL228741B1 (pl) 2018-05-30
UA88599C2 (ru) 2009-11-10
US20040082764A1 (en) 2004-04-29
IL164946A0 (en) 2005-12-18
NO2017061I1 (no) 2017-11-21
IL230659A0 (en) 2014-03-31
KR101125524B1 (ko) 2012-03-22
KR101062628B1 (ko) 2011-09-07
TW200404005A (en) 2004-03-16
KR20110050753A (ko) 2011-05-16
MXPA04010792A (es) 2005-03-07
LUC00044I1 (pl) 2017-11-03
EP3127553A1 (en) 2017-02-08
JP2013163678A (ja) 2013-08-22
TW201231089A (en) 2012-08-01
PT2371392E (pt) 2015-10-07
PH12013501159B1 (en) 2015-12-02
US20120213804A1 (en) 2012-08-23
PH12013501159A1 (en) 2015-12-02
NO20044663L (no) 2005-01-25
EP1507556B1 (en) 2016-07-27

Similar Documents

Publication Publication Date Title
PL410218A1 (pl) Sposób wytwarzania stabilnej liofilizowanej kompozycji obejmującej monomeryczne koniugaty pochodna kalicheamycyny/przeciwciało anty-CD22, kompozycja otrzymana tym sposobem oraz jej zastosowanie
EA200801460A1 (ru) Рекомбинантные моновалентные антитела и способы их получения
CR10273A (es) &#34;anticuerpos anti-5t4 y usos de los mismos&#34;
CY1112862T1 (el) Θραυσματα μονοσθενους αντισωματος χρησιμα ως θεραπευτικα
EA200900492A1 (ru) Молекулы антител, которые связываются с il-17a и il-17f
CY1118053T1 (el) Φαρμακευτικες συνθεσεις με ανθεκτικοτητα σε διαλυτο cea
ZA200702879B (en) Single domain antibodies against TNFR1 and methods of use therefor
CY1115147T1 (el) Εξουδετερωτικα αντισωματα που εχουν ειδικοτητα για ανθρωπινη il-17
CY1113243T1 (el) Μεθοδοι θεραπειας με χρηση αντισωματων cτlα-4
CY1110700T1 (el) Ανασυνδυασμενα αντισωματα αντι-cd30 και χρησεις αυτων
NO20083895L (no) Anti-IGF-1R human monoklonalantibody formulering
CY1114904T1 (el) Prlr-ειδικο αντισωμα και χρησεις αυτου
CY1116632T1 (el) Εξουδετερωτες αντισωματων του τελεστη διεγερσης αποικιων κοκκιοκυτταρων μακροφαγων ανθρωπου
EA200900040A1 (ru) Молекулы антител, которые связываются с человеческим il-17
CY1116506T1 (el) Αντισωματα εναντι masp-2
TW200505942A (en) Antibody molecules having specificity for human IL-1β
IL191617A (en) An antibody linked to polyubiquitin, a method for its preparation, a pharmaceutical preparation containing it and its uses
WO2008134724A3 (en) Methods for administering anti-il-5 antibodies
BRPI0416141B8 (pt) anticorpo anti-cd52 modificado, composição farmacêutica, vetores de expressão, e método para preparar uma imunoglobulina
TW200728466A (en) Antibody molecules having specificity for human IL-6
CY1110541T1 (el) Φαρμακευτικα σκευασματα με βελτιωμενες φαρμακευτικες ιδιοτητες που περιεχουν βελτιωτικα γευσης
ZA200508389B (en) Humanized antibodies to interferon alpha receptor-1(IFNAR-1)
DE602004017326D1 (de) Tetrahydrocarbazolderivate und deren pharmazeutische verwendung
BR0307518A (pt) Composição farmacêutica
EA200601288A1 (ru) Производные 1,3-дифенилпроп-2-ен-1-она, способ их получения и применение